Kilitch Drugs (India) Limited, a leading player in the healthcare industry, is entering the Rs 600-crore eye-care market with the launch of its new company- Eyekare Kilitch Ltd, a top company official said.
"Eyekare Kilitch will be launching 15 eye-care products in the first-year and the same will be scaled-up to 25 in the second year. The plan is to secure a 2 per cent marketshare in the first year which works out to about Rs 10-crore and to increase the same to 25 per cent over a period of five years," Kilitch Drugs Managing Director, Mukund P Mehta, told PTI here.
Kilitch Drugs (India) Ltd., will initially hold 100 per cent capital, with the equity capital being Rs 20-crore as a project advance.
Industry estimates put the annual growth rate at 12 per cent for the eye-care products market, Mehta said.
The company will produce world-class ophthalmologic products using state-of-the-art infrastructure. These products are select and specialised, based on market research data and in consultation with medical specialists and include those that are widely used and other innovative eye preparations.
Kilitch Drugs (India), the parent company, is engaged in the manufacture of injectibles such as gentamycin sulphate, dexamethason sodium phosphate, B-complex and others.
The company's products include Faropenem, Kinem, K-Penem, Cefaclor, Cefadroxil, Cefdinir, Cefpodoxime, Cefprozil, Kefperaz, Kefperaz SB, Kefperaz TZ, Kezolin, K-Furox, Kilpirome and K-Pime.
It is a regular and established supplier to MNCs and Indian pharma giants like Ranbaxy, Zydus Cadila, Emcure, USV, E-Merck and Piramal Healthcare.
Kilitch already has major exports to the Gulf countries and African nations like Kenya, Uganda, Congo, Tanzania, Ghana, Yemen and Ethiopia as also neighbouring Sri Lanka, Mehta said.
Kilitch Drugs (India) reported 14.93 per cent rise in sales to Rs 32.03-crore in Q3 FY 10 as against Rs 27.87-crore in the same period of the previous year. The company is expecting its turnover to cross Rs 160-crore in FY 10 from Rs 130-crore registered in the last fiscal year.
